Free tool
FAERS Monitor: Osphena
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 203505 or its brand name (Osphena, Ospemifene). Reports on generic versions are filed under their own applications.
Reports
2,605
Serious
481
18% of reports
Hospitalization
120
Death reported
4
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use452
- hot flush372
- headache209
- muscle spasms194
- no adverse event173
- vaginal haemorrhage150
- vaginal discharge134
- labelled drug-drug interaction medication error111
- nausea108
- hyperhidrosis107
- drug ineffective94
- rash88
- fatigue86
- pain in extremity78
- therapeutic response unexpected75
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2013 | 93 |
| 2014 | 491 |
| 2015 | 446 |
| 2016 | 589 |
| 2017 | 285 |
| 2018 | 419 |
| 2019 | 108 |
| 2020 | 49 |
| 2021 | 37 |
| 2022 | 19 |
| 2023 | 21 |
| 2024 | 17 |
| 2025 | 17 |
| 2026 | 14 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,554 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| vaginal dischargeSignal | 134 | 108.3 | 91.7 | 13,959 |
| labelled drug-drug interaction medication errorSignal | 111 | 102.6 | 85.5 | 10,937 |
| hot flushSignal | 372 | 40.0 | 36.4 | 14,104 |
| vaginal haemorrhageSignal | 150 | 28.0 | 24.0 | 3,872 |
| therapeutic response unexpectedSignal | 75 | 13.5 | 10.8 | 857 |
| muscle spasmsSignal | 194 | 8.5 | 7.5 | 1,294 |
| no adverse eventSignal | 173 | 7.7 | 6.7 | 1,012 |
| hyperhidrosisSignal | 107 | 6.7 | 5.6 | 517 |
| off label useSignal | 452 | 4.2 | 3.8 | 1,132 |
| headacheSignal | 209 | 2.7 | 2.4 | 227 |
| pain in extremitySignal | 78 | 2.1 | 1.7 | 47 |
| rash | 88 | 1.6 | 1.3 | 21 |
| nausea | 108 | 1.1 | 0.9 | 1 |
| fatigue | 86 | 0.9 | 0.7 | 1 |
| drug ineffective | 94 | 0.6 | 0.5 | 31 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.